ENOB - Enochian Bio rallies 29% on case report of complete remission in brain tumor

Enochian BioSciences (ENOB), up 29% premarket and Seraph Research Institute ((SRI)) announce that a 36-year old patient with recurrent glioblastoma achieved complete remission for a period of 15 months. A complete remission response such as this is uncommon for this highly aggressive and deadly form of brain cancer. In compliance with FDA guidance, SRI treated the patient with natural killer ((NK)) and dendritic cells ((DC)) from a relative who had a partial genetic mismatch.The DCs were loaded with a component of cytomegalovirus that is known to be present in more than 90% of glioblastomas.Enochian is also developing this enhanced immune technology, including proof-of-concept in vivo studies of the potential to clear tumors with a focus on pancreatic cancer.

For further details see:

Enochian Bio rallies 29% on case report of complete remission in brain tumor